SGLT2 inhibitors inhibit PT sodium reabsorption and glucose uptake, leading to glycosuria and natriuresis.Emerged as significant therapeutic alternatives for type 2 DM and HF.Positive impacts on patient mortality, cardiovascular outcomes and the progression of kidney disease. Here, SLC5A2 is linked to kidney disorder.